Kiromic Biopharma Inc Stock Price, News & Analysis

Kiromic BioPharma (NASDAQ: KRBP) reported significant progress in Q1 2022, focusing on immuno-oncology through its proprietary DIAMOND® AI platform. Key achievements include advancements in the ALEXIS Gamma Delta T cell platform and the redesign of its cGMP manufacturing facility. Financially, the company reported cash reserves of $15.1 million, a decrease from $25.4 million at year-end 2021. R&D expenses rose by 55.2% to $2.9 million, while G&A expenses surged by 114.4% to $4.4 million, leading to a net loss of $7 million, up from $3.9 million in the prior year.

Kiromic BioPharma, Inc. (NASDAQ: KRBP) announces progress addressing FDA CMC issues related to its Investigational New Drug Applications (INDs). The company will submit an amended IND for its oncology cell therapy candidate Procel™ in the second half of 2022, bypassing a planned Type A FDA meeting. Additionally, Kiromic is advancing the establishment of a current good manufacturing practice mammalian master cell bank, a critical component for producing GMP-grade retroviral vectors necessary for Gamma Delta T-cell engineering. CEO Pietro Bersani highlighted these developments as integral to initiating clinical trials for Procel™ by Q4 2022.

Kiromic BioPharma, Inc. (NASDAQ: KRBP) has made its latest corporate presentation available, focusing on its innovative use of the DIAMOND AI platform for developing immuno-oncology therapies. The presentation provides insights into the company’s strategic goals and its allogeneic CAR-T cell therapy platform, ALEXIS. This platform is designed to target solid tumors using gamma delta T-cells. The updated information can be accessed on the investor relations section of Kiromic's website, and the presentation has been filed with the SEC.

Kiromic BioPharma, Inc. (NASDAQ: KRBP) reported substantial advancements in its research and development efforts, particularly in its ALEXIS Gamma Delta T cell platform. The company completed 90% of its cGMP facility expansion and launched DIAMOND® AI 2.0, which now encompasses nearly two billion data points for immunotherapy target identification. For the fiscal year ended December 31, 2021, Kiromic's cash position rose to $25.35 million, while R&D expenses surged by 125% to $11.37 million, contributing to a net loss of $25.59 million, up from $19.20 million the previous year.

Kiromic BioPharma, Inc. (NASDAQ: KRBP) has filed a Form 12b-25 with the SEC seeking a 15-day extension to submit its Annual Report on Form 10-K for the fiscal year ended December 31, 2021. The company anticipates that the filing will occur within the extension period. Kiromic focuses on developing cell and gene therapies, leveraging its proprietary DIAMOND® AI platform to target immuno-oncology applications. The firm aims to enhance the development timeline and reduce costs of bringing innovative therapies to market.

Kiromic BioPharma (NASDAQ: KRBP) reported significant advancements in Q3 2021, including an expansion of its DIAMOND® AI platform to over 1.5 billion data points, reflecting a 25% increase. The completion of the InSilico Solutions acquisition, bolstering AI-driven research, and a public offering generating $37.1 million net proceeds were notable highlights. Financially, cash equivalents rose to $36.2 million; however, R&D expenses surged by 184% to $3.5 million, reflecting increased operational costs. The net loss decreased slightly to $14.95 million year-to-date.

Kiromic BioPharma (NASDAQ: KRBP) announces management changes effective January 27, 2022. Pietro Bersani is appointed as Interim CEO, succeeding Dr. Maurizio Chiriva, who has left the company. Michael Nagel is named the new Chairman of the Board. The company also establishes a Disclosure Committee to enhance its disclosure protocols. Bersani emphasized the importance of reaching key clinical trial milestones in the upcoming year, focusing on first-in-human dosing and clinical trial initiation.

Kiromic BioPharma (NASDAQ: KRBP) has appointed Frank Tirelli as Chair of the Audit Committee and Karen Reeves, M.D. to its Board of Directors. Tirelli, a CPA with extensive experience at Deloitte, is expected to enhance financial reporting capabilities. Reeves brings over 25 years of biopharmaceutical expertise, notably in clinical R&D and regulatory affairs. Both appointments aim to strengthen the board during critical developments in Kiromic's immuno-oncology pipeline, leveraging its proprietary DIAMOND® AI platform for innovative therapies.

Kiromic BioPharma, Inc. (NASDAQ: KRBP) announced it received a notice from Nasdaq on November 18, 2021 regarding non-compliance with listing requirements due to the late submission of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2021. The company has 60 days to submit a compliance plan, potentially getting an extension of up to 180 days. The notice does not affect trading of the company's securities. Kiromic is focused on developing cell and gene therapies, including CAR-T cell therapies.